Biological effects of SHP2 inhibition combining with anti-PD1 antibody in EGFR activated versus non-activated tumors (PRJCA049438)
To evaluate the biological effect and transcriptome change of SHP2 inhibition combining with anti-PD1 antibody in B16F10-derived subcutaneous tumor models.